Balkan Endemic Nephropathy — Comprehensive Research Report

Prepared: 2026-09-01 · Target: MONDO:0007416 · Category: Complex (environmental toxin + host susceptibility)

0. Orientation — the one-paragraph version

Balkan Endemic Nephropathy (BEN) is a slow, quiet, scarring kidney disease that ate its way through specific farming villages along the Danube tributaries for most of the 20th century. It looks like a genetic disease from a distance — it clusters in families — but it clusters in households, not bloodlines, which is the tell. The cause is aristolochic acid (AA), a phytotoxin from the birthwort Aristolochia clematitis, a weed that grew in the wheat and whose seeds went into the flour and then into home-baked bread. Think of it as a very slow, very patient poisoning administered one loaf at a time over decades. The toxin's activated metabolite sticks to DNA at adenine, sits there essentially uncleaned by repair machinery, and eventually writes a fingerprint mutation (A:T→T:A) into TP53 and the rest of the genome — which is why the same villages that got kidney failure also got a bewildering excess of urinary-tract cancer. Modern agriculture accidentally cured it: bigger mills and better sieves in the 1970s stopped separating badly, and the disease is now fading.

1. Disease Information

1.1 Overview

BEN is a chronic tubulointerstitial nephropathy with insidious onset, near-invariable progression to end-stage renal disease (ESRD), and a strong association with upper tract urothelial carcinoma (UTUC) of the renal pelvis and ureter.

"Balkan endemic nephropathy is a chronic tubulointerstitial disease with insidious onset, slowly progressing to end-stage renal disease and frequently associated with urothelial carcinoma of the upper urinary tract (UTUC). It was described in South-East Europe at the Balkan peninsula in rural areas around tributaries of the Danube River." — Jelaković et al., Semin Nephrol 2019 (PMID:31054628)

"Endemic (Balkan) nephropathy (EN), a devastating renal disease affecting men and women living in rural areas of Bosnia, Bulgaria, Croatia, Romania, and Serbia, is characterized by its insidious onset, invariable progression to chronic renal failure and a strong association with transitional cell (urothelial) carcinoma of the upper urinary tract." — Grollman et al., PNAS 2007 (PMID:17620607)

1.2 Key identifiers

Resolved against MONDO via OLS4 this session:

MONDO definition (verbatim): "A chronic tubulointerstitial nephropathy that affects people in certain rural areas along the Danube river in the Balkans. It leads to end-stage renal disease."

Not found: no Orphanet cross-reference appears in the MONDO record. BEN is an environmental disease of defined geography rather than a rare Mendelian disorder, which likely explains the absence — but treat this as "not confirmed" rather than "confirmed absent."

Watch-out on OMIM 124100. That entry frames BEN as a familial/Mendelian condition and preserves several claims that are now superseded: it repeats the Pliocene-lignite/polycyclic-aromatic-hydrocarbon hypothesis and states that "the histologic end stage of the kidney lesion is thought to be a form of primary amyloidosis." Neither reflects current understanding. Cite OMIM for the identifier and the historical framing; do not cite it for mechanism.

1.3 Synonyms (from MONDO)

Balkan endemic nephropathy · endemic nephropathy · Danubian endemic familial nephropathy (DEFN) · Chinese herb endemic nephropathy · aristolochic acid nephropathy (AAN) · BEN

⚠️ Curation decision flagged: MONDO lists "aristolochic acid nephropathy" and "Chinese herb endemic nephropathy" as synonyms of BEN. This reflects De Broe's 2012 argument (PMID:22373701, "Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy") that they are one disease. They share etiology, pathology, and cancer risk — but not clinical course. See §1.4. If dismech models BEN as an entry, the AAN-vs-BEN relationship is a real lump/split call, and the honest answer is probably: BEN is the environmental, low-dose, chronic presentation of AAN, and iatrogenic/herbal AAN is the high-dose, rapid presentation. A Grouping over both, or has_subtypes, would capture it better than treating them as one flat concept.

1.4 BEN vs. iatrogenic AAN — the contrast table

Reproduced from Table 1 of Jelaković et al. 2019 (PMID:31054628):

The course difference is dose-driven: Balkan exposure was micrograms over decades; Belgian exposure was a large cumulative dose over months.

1.5 Information provenance

Information here is aggregated disease-level — epidemiologic field surveys, autopsy and nephrectomy series, molecular-epidemiologic cohorts, and consensus statements. It is not EHR-derived. Two data types are genuinely individual-patient-level and are the ones that carry the causal argument: (a) 32P-postlabeling / LC-MS/MS aristolactam-DNA adduct measurements in renal cortex, and (b) TP53 / whole-exome / whole-genome sequencing of tumors.

2. Etiology

2.1 Primary causal factor — aristolochic acid

Chronic, low-dose dietary ingestion of aristolochic acid from Aristolochia clematitis (birthwort), a weed that grows amid wheat in the Danube floodplain. Its seeds are comparable in size to wheat grain and were carried through village milling into flour, and then into home-baked bread.

The hypothesis is old — Ivić proposed it in 1969 — and sat ignored for ~35 years until the Belgian "Chinese herb nephropathy" outbreak made the pathology look familiar:

"In 1969, Ivic had suggested that the latter, occurring in certain villages throughout the Danube Valley, might be caused by the chronic ingestion of the seeds of the Aristolochia clematitis, a common plant growing in the wheat fields of these endemic regions." (PMID:31054628)

The chemistry: AA is a mixture of nitrophenanthrene carboxylic acids, dominated by aristolochic acid I (AAI) and aristolochic acid II (AAII). Both are mutagenic and genotoxic; AAI is considered the nephrotoxic actor (PMID:31054628).

IARC classification: herbal remedies containing Aristolochia species, and aristolochic acids themselves, are Group 1 (carcinogenic to humans), acting by a genotoxic mechanism (PMID:31054628; IARC Monographs).

2.2 The causal evidence chain (five independent lines)

1. Botanical/agricultural — A. clematitis seeds co-mingle with harvested wheat in endemic Croatian and Serbian villages (Hranjec et al. 2005, cited in PMID:31054628).
2. Analytical chemistry — AA is quantifiable in corn, wheat grain, and soil from the endemic Serbian village of Kutleš (Chan et al., J Agric Food Chem 2016, PMID:27362729), establishing crop uptake from contaminated soil as a second exposure pathway beyond seed co-mingling.
3. Molecular dosimetry — aristolactam-DNA adducts in renal cortex of BEN patients and not in other CKD (PMID:17620607).
4. Mutational fingerprint — the AA-specific A:T→T:A transversion in TP53 and genome-wide (PMID:17620607, PMID:22071594, PMID:23926199).
5. Natural experiments in migration — Ukrainians who settled Croatian endemic villages acquired local BEN risk after >20 years; those who settled non-endemic villages did not; BEN has never been reported in Ukraine (Čeović 1985, in PMID:31054628). This kills inheritance as the primary driver.

2.3 Environmental risk factors

Explicitly NOT a risk factor: herbal teas / herbal medicine use in the Balkan setting. A cohort of >2,500 Croatian farmers rejected this (Ivković et al. 2014, cited in PMID:31054628). Worth curating as a REFUTE evidence item — it's a real negative result that distinguishes Balkan from Asian AAN.

2.4 Genetic risk factors

There is no causal Mendelian gene. What exists is candidate susceptibility, and it is thin:

Be honest about the state of this literature. The 2019 review is blunt:

"However, studies evaluating genetic polymorphisms of AA-metabolising enzymes have only resulted in controversial results ... and thus this phenomenon remains to be further investigated." (PMID:31054628)

There is no published GWAS of BEN meeting modern standards that I could locate. The candidate-gene studies are small (n ≈ 200–350) and unreplicated. Curate them as SUSCEPTIBILITY, never CAUSATIVE.

2.5 Protective factors

• Modern milling and combine harvesting (post-1970s): larger central mills and finer sieves separate the larger Aristolochia seeds from wheat. This is the actual population-level protective intervention, and it happened by accident. (PMID:31054628)
• Immigrant status in the post-improvement era: Bosnians who settled Croatian endemic villages after the agricultural improvements showed immigrant status as a protective predictor for proximal tubule damage — the exact inverse of the 1950s Ukrainian result. This is a beautiful natural experiment and the single strongest argument that agricultural practice, not soil or geology, sets the dose. (PMID:31054628)
• Avoiding AA-containing herbal preparations — regulatory bans (FDA 2001 and equivalents).
• Genetic protective alleles: none established. Wild-type GPX3/MDR1 by implication only.

2.6 Gene–environment interaction

This is the mechanistic core of the disease and belongs in the KB as an explicit GxE claim:

"Thus, in genetically susceptible individuals, dietary exposure to aristolochic acid is causally related to endemic nephropathy and carcinomas of the upper urinary tract." — PMID:22071594

Only 2–5% of exposed villagers develop BEN, while ~10–15% of farmers are "suspected." The proposed interaction axes: 1. Bioactivation vs. detoxification balance — NQO1/POR/CYP1A1/1A2/COX (activating) vs. CYP-mediated O-demethylation to AAIa (detoxifying). "Differences in AA metabolism (activation versus detoxification) might not only contribute to an individual's susceptibility but could also be an important determinant of cancer risk." (PMID:31054628) 2. Antioxidant capacity — GPX3, Nrf2, KEAP1, GSTP1, SOD2, GPX1 (PMID:37629712). 3. Efflux transport — MDR1/ABCB1. 4. DNA repair capacity — dA-AAI adducts are poorly excised by nucleotide-excision repair. 5. Clinical-course modification — "different clinical courses do not seem to be related to differences in exposure, but more likely to differences in metabolic activation or detoxification of AA and/or DNA repair resulting from different genetic polymorphisms." (PMID:31054628)

3. Phenotypes

BEN is phenotypically quiet. That is its defining clinical feature and its public-health problem — patients present late because there is nothing to present with.

"There is no leading typical symptom (fatigue, loss of appetite, nocturia, polyuria)." (PMID:31054628)

3.1 Phenotype table with suggested HP terms

All HP IDs below were resolved against OLS4 (hp) in this session unless marked otherwise.

Iatrogenic AAN only (not BEN): HP:0001994 Renal Fanconi syndrome, HP:0003076 Glycosuria, HP:0003355 Aminoaciduria. Do not attach these to BEN — they belong to the high-dose form.

3.2 The three clinical courses

Explicitly enumerated in PMID:31054628 — a good candidate for progression: phases or subtype modeling:

1. Chronic tubulointerstitial nephropathy alone → ESRD.
2. Simultaneous UTUC (unilateral or bilateral) + renal impairment + typical BEN histopathology.
3. Initial deterioration of kidney function, followed later by UTUC (unilateral or bilateral).

3.3 Quality of life

No BEN-specific EQ-5D / SF-36 / PROMIS/KDQOL data located. This is a genuine literature gap. Reasonable inferences (mark as such, not as findings): - The pre-ESRD phase is near-asymptomatic — QoL impact is likely minimal until CKD stage 4–5. - Dialysis dependence, and bilateral nephroureterectomy in transplant candidates, dominate the QoL burden. - Note a paradoxically favorable vascular finding: "lower arterial stiffness and slower vascular aging was reported in Croatian and Bosnian BEN patients undergoing dialysis compared to other ESRD patients" (PMID:31054628) — later-onset, milder hypertension.

4. Genetic / Molecular Information

4.1 Causal genes — none

BEN has no germline causal gene. This is the single most important negative statement in the entry. Household clustering without bloodline clustering, plus the Ukrainian migration experiment, ruled inheritance out:

"Inherited pattern of the disease was ruled out by the fact that BEN often affected several members of the same household not necessarily blood related." (PMID:31054628)

The genetics that matter are somatic and downstream of the exposure.

4.2 Somatic mutations — the aristolochic acid signature

TP53 (hgnc:11998) is the flagship:

"Mutations at A:T pairs accounted for 89% of all p53 mutations, with 78% of these being A:T --> T:A transversions." — PMID:17620607

Adduct–mutation coupling in the same patients:

"Adducts were present in 70% of the endemic cohort and in 94% of patients with specific A:T to T:A mutations in TP53. In contrast, neither aristolactam-DNA adducts nor specific mutations were detected in tissues of patients residing in nonendemic regions." — PMID:22071594

Genome-wide characterization (Poon et al., Sci Transl Med 2013, PMID:23926199):

"Whole-genome and exome analysis of nine AA-associated UTUCs revealed a strikingly high somatic mutation rate (150 mutations/Mb), exceeding smoking-associated lung cancer (8 mutations/Mb) and ultraviolet radiation-associated melanoma (111 mutations/Mb). The AA-UTUC mutational signature was characterized by A:T to T:A transversions at the sequence motif A[C|T]AGG, located primarily on nontranscribed strands."

Same paper: AA mutations were enriched at splice sites, with RNA-seq confirming aberrant splicing and up-regulated nonsense-mediated decay machinery; and a high frequency of somatic mutation in chromatin modifiers, particularly KDM6A.

COSMIC / SBS22 is the formal signature name. Exome sequencing of 15 BEN patients with urothelial carcinoma identified Signature 22 plus a driver-gene list (PMID:31054628, citing Scelo et al.):

TP53, AHNAK, ARID1B, ATRX, BLM, CHD2, CHD5, CHD8, CHD9, CHEK2, CLTC, ERBB4, FN1, HUWE1, IARS2, KALRN, LRRK2, MLL2 (KMT2D), NEB, RXRA, SMCHD1, SPEG, STAG2, SYNE1, TRIO

Functional themes: transcriptional regulation, chromatin/histone modification, DNA damage response, DNA repair.

Somatic vs germline: every AA-attributable variant discussed here is somatic, arising in renal tubular and urothelial cells after adduct formation. Nothing is inherited. Curate variant_origin: SOMATIC.

Variant class: point substitutions, overwhelmingly A:T→T:A transversions, strand-biased to the non-transcribed strand (which is why they persist — transcription-coupled repair never sees them).

4.3 The newest and biggest result — Senkin et al., Nature 2024

This is the most important recent development and expands the exposure map substantially. 962 clear cell renal cell carcinomas sequenced across 11 countries:

"In Romania, Serbia and Thailand, mutational signatures characteristic of aristolochic acid compounds were present in most cases, but these were rare elsewhere." — Senkin et al., Nature 2024;629(8013):910–918, PMID:38693263

Country-level SBS22 burden: Romania 45/64 (70%), Serbia 16/69 (23%), Thailand 3/5 (60%). Implication: AA exposure is far more geographically widespread than the classical BEN foci — potentially millions of people.

4.4 The renal cell carcinoma question — an open issue worth curating as a knowledge gap

Classical BEN cohorts report urothelial carcinoma, not RCC. But:

"We detected dA-AL-I in the 14 Romanian cases at levels ranging from 0.7 to 27 adducts per 10(8) DNA bases, in line with levels reported in Asian and Balkan populations exposed through herbal remedies or food contamination. The 15 cases from other countries were negative." — Turesky et al., Br J Cancer 2016, PMID:26657656

"Although the source of exposure is uncertain and likely different in AAN regions than elsewhere, our results demonstrate that AA exposure in Romania exists outside localised AAN regions and provide further evidence implicating AA in RCC." — PMID:26657656

Also: Hoang et al., Int J Cancer 2015, "Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid" (PMID:25403517).

But the 2019 review is careful: "RCC have not been reported in BEN patients but studies in Asia (Taiwan) have linked AA exposure to this cancer type... it is clear that these patients do not cover the Romanian population of the BEN area" (PMID:31054628).

Suggested KB treatment: a discussions: entry with kind: KNOWLEDGE_GAP — is AA-associated RCC a genuine BEN phenotype, an exposure-without-BEN phenotype, or a different exposure route in the same countries? The 2024 Nature result (23% of Serbian ccRCC) pushes toward "real and under-recognized."

4.5 Modifier genes

See §2.4. GPX3 rs8177412 is the best-supported effect modifier (8-fold for tumor risk, PMID:37629712). Nrf2 rs6721961, KEAP1 rs1048290, GSTP1 rs1695/rs1138272, MDR1 rs1045642 were tested in the same study; only the GPX3 tumor association and the GPX3+MDR1 female combination reached significance.

4.6 Epigenetics

Whole-genome methylation array analysis of BEN patients: Staneva et al., BMC Nephrol 2013 (PMID:24131581). Reported differential methylation relevant to BEN etiology. This work is small and unreplicated; I did not locate independent confirmation. Curate cautiously, or note as a gap. AAI is also reported to alter DNA methylation and histone marks in tubular cells, but I have not verified a specific primary source in this session — flag as unverified.

4.7 Chromosomal abnormalities

Only the historical 3q25–3q26 cytogenetic marker (PMID:8730422, 1996). No modern CMA/karyotype/dbVar-supported structural finding. Do not curate as established.

5. Environmental Information

5.1 The causal agent

• Aristolochic acid I (AAI) — CHEBI:2825 (⚠️ canonical CHEBI label is "aristolochic acid A", not "aristolochic acid I" — dismech's exact-label rule means preferred_term: aristolochic acid I with term.label: aristolochic acid A)
• Aristolochic acid II (AAII) — CHEBI:194149 "aristolochic acid B"
• Aristolactam I — CHEBI:235435 "Aristolactam I"
• Source organism: Aristolochia clematitis L. (European birthwort). NCBI Taxonomy ID not verified this session — look it up before binding.
• ECTO exposure term: ECTO:9002244 "exposure to aristolochic acid A" (verified via OLS4) — this is the right binding for the environmental[] exposure_term.

5.2 Exposure routes (both should be influences_mechanisms links)

1. Home-baked bread from wheat contaminated with A. clematitis seed — the dominant historical route. Chronic, low-dose, decades-long.
2. Crops grown in AA-contaminated soil — AA quantified in corn and wheat grain from endemic Serbian villages (PMID:27362729). Chan et al. "hypothesized that AA present in edible parts of crops originating from AA-contaminated soil could be one of the pathways by which AA could enter the human food chain" (PMID:31054628).
3. (Elsewhere, not BEN) herbal remedies — TCM, Kampo, Ayurvedic; genus names Mu Tong, Mokutsu, Fang ji.

5.3 Competing / rejected etiologies

Curate these as REFUTE evidence or historical notes — they matter because the older BEN literature is dense with them.

The pivotal external assessment: Voice et al. 2006 concluded that among suspected environmental agents, mycotoxins and AA are the primary targets (cited in PMID:31054628) — and the mycotoxin arm has since collapsed.

5.4 Lifestyle factors

• Subsistence farming, wheat cultivation, home bread-baking — the exposure vehicle.
• Recent CKD-risk drift: "the prevalence of hypertension in BEN villages does not differ from other rural parts of Croatia, very probably reflecting changes in lifestyle (high salt intake), obesity and more stress" (PMID:31054628). Modern comorbidity is diluting the historically distinctive normotensive phenotype.

5.5 Infectious agents

Not applicable. Infectious etiologies were investigated and rejected.

6. Mechanism / Pathophysiology

6.1 The ordered causal chain

Numbered, initiating lesion → clinical manifestation. Steps marked (inferred) are mechanistically reasoned rather than directly demonstrated in BEN patients.

1. Aristolochia clematitis seeds co-mingle with harvested wheat and enter village flour → chronic low-dose oral aristolochic acid (AAI/AAII) exposure over decades. (PMID:31054628, PMID:27362729)
2. Ingested AAI is absorbed from the gut and enters the portal circulation → systemic AAI burden. (inferred; standard pharmacokinetics)
3. Hepatic nitroreduction of AAI — cytosolic NQO1 plus microsomal POR and CYP1A1/1A2 reduce the nitro group → leads to aristolactam metabolites, including N-hydroxyaristolactam, which is sulfate-conjugated (AL-I-N-OSO₃). This is the bioactivation branch. (PMID:31054628; NQO1 dependence shown by dicoumarol inhibition, PMID:21613233)
4. Competing branch — detoxification: CYP-mediated O-demethylation of AAI yields AAIa (8-hydroxy-AAI), lowering effective AAI. The activation:detoxification ratio is the proposed susceptibility switch. (PMID:31054628)
5. Reactive conjugate is exported from hepatocytes (MRP3/MRP4) and delivered to the kidney → results in presentation of AAI/AL-I-N-OSO₃ at the peritubular capillary. (partly inferred — the MRP arm is from a human liver–kidney co-culture model, PMID:29202460)
6. Basolateral uptake into proximal tubule epithelial cells by organic anion transporters OAT1 (SLC22A6) and OAT3 (SLC22A8) → causes intracellular concentration far above plasma. This is the step that makes the disease proximal-tubule-selective rather than generally toxic.

   "Aristolochic acid I (AAI), the more cytotoxic and genotoxic AA congener, exhibited high affinity for hOAT1 (K(i)=0.6 microM) as well as hOAT3 (K(i)=0.5 microM), and lower affinity for hOAT4 (K(i)=20.6 microM)." — PMID:19643159 "Uptake by slices was sensitive to known mOat1 and mOat3 substrates and the organic anion transport inhibitor probenecid, which also blocked the production of DNA adducts formed with reactive intracellular metabolites of AA-I." — PMID:21546538

7. Intracellular nitroreduction (renal NQO1, COX in urothelium) generates a cyclic N-acylnitrenium ion → the ultimate electrophile.

   "a cyclic N-acylnitrenium ion with a delocalised positive charge (aristolactam-nitrenium ion) is the ultimate electrophilic species that binds preferentially to the exocycylic amino groups of purine nucleotides in DNA through the C7 position of the phenanthrene ring." — PMID:31054628

From step 6 the chain branches. Both branches are needed to explain BEN.

BRANCH A — the fibrotic/renal-failure arm

7A. Nitrenium ion + reactive oxygen species attack proximal tubule epithelial cells → results in acute tubular epithelial cell injury and necrosis. (directly demonstrated in rodents; inferred as the initiating step in humans, whose exposure was too slow to observe an acute phase) 8A. Necrotic tubular cells release HMGB1 and mitochondrial DNA → activates TLR signaling and sterile inflammation. (PMID:35765703) 9A. Interstitial recruitment of activated monocytes/macrophages, then cytotoxic T lymphocytes → transient AKI episode. (PMID:35602498) 10A. Peritubular capillary rarefaction and interstitial hypoxia → worsens tubular ischemia. (rat model) 11A. Surviving tubular epithelium dedifferentiates; resident fibroblasts activate into TGF-β–expressing, αSMA/vimentin-positive myofibroblasts → causes collagen deposition.

"The accumulation of vimentin and αSMA-positive cells expressing TGFβ in interstitial areas suggested an increase in resident fibroblasts and their activation into myofibroblasts resulting in collagen deposition and CKD." — PMID:35602498 12A. Progressive hypocellular interstitial fibrosis with tubular atrophy, worst in outer cortex, decreasing inward → produces the pathognomonic corticomedullary gradient. 13A. Loss of erythropoietin-secreting peritubular interstitial cells → causes anemia disproportionate to CKD stage. (PMID:31054628) 14A. Loss of tubular concentrating and salt-handling capacity → hyposthenuria, polyuria, nocturia, salt wasting → explains the characteristically normal early blood pressure. 15A. Nephron loss → declining GFR → ESRD in the 6th–7th decade, with symmetric, smooth, 20–30 g contracted kidneys.

BRANCH B — the carcinogenic arm

7B. Nitrenium ion binds the exocyclic amino groups of dA and dG → forms 7-(deoxyadenosin-N⁶-yl)aristolactam I (dA-AAI) — the dominant, remarkably persistent adduct — plus dG-AAI, dA-AAII, dG-AAII. (PMID:17620607, PMID:31054628) 8B. dA-AAI is poorly excised by nucleotide-excision repair, and sits preferentially on the non-transcribed strand where transcription-coupled repair cannot reach it → results in adduct persistence for decades. Curate this as its own node — persistence, not just formation, is what makes a decades-latency cancer possible. 9B. Replication past the persistent dA adduct mispairs → produces A:T→T:A transversions at the A[C|T]AGG motif. 10B. Transversions accumulate in TP53 and genome-wide (KDM6A, chromatin modifiers, DNA-repair genes), plus splice-site enrichment → causes loss of tumor-suppressor function and aberrant splicing, at an extreme mutation burden (~150 mut/Mb). (PMID:23926199) 11B. Malignant transformation of urothelium → upper tract urothelial carcinoma in 30–50% of BEN patients, frequently bilateral, and (per the 2024 Nature data) also clear cell renal cell carcinoma in AA-exposed populations.

Amplifier feeding both branches: AA metabolism generates reactive oxygen species → oxidative distress → both cytotoxicity (Branch A) and additional oxidative DNA lesions (Branch B). Antioxidant-gene variants (GPX3) modulate this, which is exactly why GPX3 hits tumor risk rather than nephropathy risk (PMID:37629712).

6.2 Molecular pathways

Other signaling nodes reported (verify each before binding): RhoA/ROCK → NLRP3 inflammasome → pyroptosis (fasudil is protective; PMID:41289940, 2026); PSTPIP2 / IL-19 / neutrophil extracellular traps; Nrf2–HO-1/GPX4 axis; pregnane X receptor → p53 ubiquitination (2026, Ren Fail).

6.3 Cell types involved (CL terms, all verified via OLS4)

"we identified 4 major actors in the AKI-to-CKD transition: (1) the tubular epithelial cells, (2) the endothelial cells of the interstitial capillary network, (3) the inflammatory infiltrate, and (4) the myofibroblasts." — PMID:35602498

6.4 Molecular profiling

• Genomics: COSMIC/SBS22 signature; driver-gene list (§4.2); ~150 mut/Mb.
• Transcriptomics: RNA-seq of AA-UTUC shows up-regulated nonsense-mediated decay machinery and aberrant splicing events tied to splice-site mutations; 68–76% of AA-specific deleterious mutations propagate to transcript level — "a possible basis for neoantigen formation and immunotherapy targeting" (PMID:34569060). Rat DrugMatrix work identified a 30-gene cluster predicting nephrotoxic potential pre-injury (PMID:31054628).
• Proteomics: differential expression of cytoskeletal, developmental, and inflammatory kidney proteins in AA-exposed vs control mice; a proteomic signature in rat kidney (PMID:31054628).
• Metabolomics: ¹H-NMR urine profiling in rats showed increased glucose, amino acids, organic acids and decreased hippurate — "indicative of an acute proximal tubule injury." Clinically, Belgian AAN and Croatian BEN patients had close urine metabolic profiles, "bringing some new evidence that both diseases have a common etiology" (PMID:31054628). That's a nice orthogonal confirmation of the lumping argument.
• Adductomics: dA-AL-I quantified by ³²P-postlabeling and LC-ESI/MS/MS³, in fresh and FFPE tissue.
• Lipidomics: no BEN-specific dataset located.
• Single-cell / spatial transcriptomics: no BEN-specific dataset located. Genuine gap — a spatial study of the outer→inner cortical fibrosis gradient would be an obvious high-value experiment.
• Functional genomics screens: no BEN-specific CRISPR/RNAi screen located.

7. Anatomical Structures Affected

All UBERON IDs verified via OLS4 this session.

7.1 Organ level

• Primary: kidney — UBERON:0002113
• Primary (second target tissue): upper urinary tract urothelium — renal pelvis UBERON:0001224, kidney pelvis urothelium UBERON:0004788, ureter UBERON:0000056, urothelium UBERON:0000365
• Secondary: urinary bladder UBERON:0001255 (late, mostly in the Belgian AAN cohort post-nephroureterectomy); hematopoietic system (EPO-deficient anemia); cardiovascular system (late CKD hypertension)
• Body systems: renal/urinary primarily; hematologic and cardiovascular secondarily

7.2 Tissue level and the corticomedullary gradient

The gradient is the signature of this disease and deserves its own node:

"The most dominant morphologic characteristic is extensive hypocellular interstitial fibrosis associated with tubular atrophy involving medullary rays, that decrease in intensity from outer medulla and the cortical labyrinth to the inner cortex." (PMID:31054628)

• Cortex of kidney — UBERON:0001225
• Outer cortex of kidney — UBERON:0002189 (worst affected)
• Renal medulla — UBERON:0000362 (medullary rays involved)
• Proximal tubule — UBERON:0004134

Glomeruli are relatively spared early — "good preservation of glomeruli" — with periglomerular fibrosis, obsolescent (collapsing-type) glomeruli, occasional TMA-like and FSGS-like lesions appearing only as the disease advances. Vascular lesions: arteriolar hyalinosis, intimal fibrous hyperplasia, occasional mucoid arterial intimal fibrosis, and multifocal thickening/splitting of peritubular capillary basement membranes.

Inflammatory infiltrate is sparse — "usually less than that might be expected in other renal diseases, were found in less than one-third of cases." This is why "hypocellular" is the operative adjective.

7.3 Subcellular level

Suggested GO cellular-component bindings (from memory — verify all before binding): nucleus (GO:0005634) for adduct formation; mitochondrion (GO:0005739) for mtDNA damage and iron overload; endoplasmic reticulum (GO:0005783) for Ca²⁺ release / ER stress; cytosol for NQO1; plasma membrane / basolateral plasma membrane for OAT1/OAT3.

7.4 Lateralization

Bilateral and symmetric for the nephropathy — "the kidneys are extremely small, symmetrically contracted, weighing only 20–30 grams each with smooth outlines." UTUC may be unilateral or bilateral, and bilaterality is common enough that the consensus recommends bilateral prophylactic nephroureterectomy pre-transplant (PMID:24166461, PMID:31054628).

8. Temporal Development

8.1 Onset

• Age: insidious onset in the fifth decade; ESRD in the sixth or seventh. Never reported in children — "indicating that long period of exposure to the environmental agent is needed" (PMID:31054628).
• Pattern: chronic, insidious. No acute presenting event, no fever, no pain, no nephritic syndrome.
• Required exposure duration: the diagnostic criteria use >20 years residency in a BEN village/household as the exposure threshold (PMID:24166461).
• Secular drift: "In last decades, the age when BEN patients start to receive dialysis was shifted to older ages, raising the question whether the etiological agent is still present or active." (PMID:31054628) — i.e. the cohort is aging out, consistent with exposure ending in the 1970s.

8.2 Progression

• Rate: slow, over years to decades. Contrast with iatrogenic AAN, which is "rapidly progressive to ESRD."
• Course pattern: progressive, monotonic. No relapsing-remitting phase, no plateau, no documented spontaneous remission.
• Duration: chronic and lifelong once established.

8.3 Patterns

• Remission: none. Removing the exposure does not reverse established injury — "the nephrotoxic effects of AA are irreversible" (PMID:31054628), and "there is no effective treatment for delaying or reversing the renal deterioration caused by AAN" (PMID:37448287).
• Critical periods / windows of opportunity:
• Before exposure — the only true prevention window (agricultural practice, grain sieving).
• The subclinical tubular-proteinuria window — the only window where screening changes anything, and what the 5-yearly mass screening exists for.
• Cancer surveillance window — because adducts persist for decades, cancer risk outlives the exposure. This is the reason surveillance must continue in people whose exposure ended 40 years ago, and it's the most counterintuitive clinical implication of the whole disease.

9. Inheritance and Population

9.1 Epidemiology

For a prevalence: block using the structured slots: 2–5% → rate_per_100000: 3500 (midpoint), rate_low: 2000, rate_high: 5000, measure_type: POINT_PREVALENCE, prevalence_class: ABOVE_1_IN_1000, population: "Adult residents of endemic Balkan villages". Do not compare that to a general-population rate — it's conditioned on residence in an endemic village.

Trend — declining, possibly toward disappearance:

"The prevalence of EN in the endemic Croatian areas appears to be decreasing. For the first time, we failed to detect any EN patients in a village that was previously considered endemic, which might indicate that EN is diminishing." — PMID:22116163

"in Croatian field surveys conducted between 2005 and 2015, where neither new BEN nor new UTUC patients were detected in some previously established BEN villages. Similar trends were observed in Serbia." — PMID:31054628

The mechanism of decline is the agricultural change of the 1970s, not any medical intervention (§2.5). But the review adds an important caveat: "in next few years, due to past exposure, new BEN patients will still start dialysis and even more importantly new BEN/UTUC patients will be diagnosed."

9.2 Inheritance

• Pattern: not inherited. Multifactorial at most — environmental exposure with polygenic susceptibility modifying penetrance. Household aggregation, not bloodline aggregation.
• Penetrance: ~2–5% among exposed. Whatever susceptibility exists is very incompletely penetrant.
• Expressivity: variable — three distinct clinical courses (§3.2).
• Anticipation: not applicable.
• Germline mosaicism: not applicable.
• Founder effects: none — the geographic clustering is ecological, not genetic, and the Ukrainian and Bosnian migration studies prove it in both directions.
• Consanguinity: no established role.
• Carrier frequency: not applicable.

If dismech models this, the inheritance: block should be either absent or explicitly documented as non-Mendelian with a note explaining the household-clustering artifact. The OMIM 124100 "familial nephropathy" framing is the thing most likely to mislead a downstream consumer.

9.3 Population demographics

• Affected populations: rural farming populations of Bosnia and Herzegovina, Bulgaria, Croatia, Romania, Serbia, in villages along tributaries of the Danube. Ethnicity is irrelevant — settlers of any origin acquired local risk after ~20 years.
• Geographic distribution: highly focal, village-level. Named endemic foci in the literature include Kaniža, Slavonski Kobaš, Dubočac (Croatia) and Vreoci, Kutleš (Serbia).
• "Sporadic BEN": cases occur outside recognized endemic villages. Nikolić et al. 2006 first proposed this; aristolactam-DNA adducts and signature mutations were subsequently found in 10 Croatian and Bosnian farmers in non-endemic villages (PMID:31054628, unpublished at time of review). The 2024 Nature data (23% of Serbian ccRCC carrying SBS22) argues strongly that exposure is far broader than the classical map (PMID:38693263).
• Sex ratio: essentially 1:1 — "There were no gender differences, although slight insignificant female predominance was found (1:1.2)." (PMID:31054628) Note the contrast with iatrogenic AAN, which is female-skewed purely because of who attended the Belgian slimming clinic — a cohort artifact, not biology.
• Age distribution: onset 5th decade; ESRD 6th–7th; zero pediatric cases.

10. Diagnostics

10.1 The headline caveat

"There are no diagnostic features which are pathognomonic of BEN." (PMID:31054628)

Diagnosis is a combination of residence history, tubular proteinuria, reduced eGFR, anemia, and imaging — with adduct/signature detection as the only truly confirmatory test.

10.2 Laboratory tests and biomarkers

Emerging / research biomarkers: urinary metabolomic profile by ¹H-NMR (Belgian AAN ≈ Croatian BEN); urinary molecular profiles in AA-UTUC (PMID:34569060); KIM-1/NGAL as generic tubular-injury markers (not BEN-specific — do not overclaim).

10.3 The confirmatory molecular tests

These are what separate BEN/AAN from every other chronic tubulointerstitial nephropathy:

1. Aristolactam-DNA adducts (dA-AL-I) in renal cortex — ³²P-postlabeling, or LC-ESI/MS/MS³ (now usable on FFPE tissue as well as fresh). Detected in 70% of an endemic UTUC cohort (PMID:22071594). Persist for decades. Levels in Romanian RCC cases: 0.7 to 27 adducts per 10⁸ DNA bases (PMID:26657656).
2. TP53 A:T→T:A transversion signature in tumor tissue.
3. Whole-exome / whole-genome sequencing → COSMIC SBS22.

The consensus asks that this be operationalized surgically: "In all UTUC patients from farming villages, renal cortex should be excised during surgery (distant from tumor) and analyzed for evidence of BEN, and if possible, should be frozen at -20°C for subsequent determination of the level of aristolactam-DNA adducts and TP53 fingerprint mutation on tumor tissue." (PMID:31054628)

10.4 Imaging and endoscopy

• Renal ultrasound — renal atrophy and nephrosclerosis; part of the diagnostic set
• CT urography — NCIT:C17204 Computed Tomography — when UTUC is suspected
• Ureteropyeloscopy — NCIT:C94308 Ureteroscopy
• Cystoscopy — NCIT:C16482 Cystoscopy — mandatory for hematuria

10.5 Biopsy / histopathology

NCIT:C51699 Kidney Biopsy. Findings (all from PMID:31054628): - Extensive hypocellular interstitial fibrosis with tubular atrophy, involving medullary rays - Corticomedullary gradient: severity decreasing outer→inner cortex - Glomeruli relatively spared early; later periglomerular fibrosis, obsolescent (collapsing-type) glomeruli, occasional TMA-like and FSGS-like lesions - Vascular: arteriolar hyalinosis, intimal fibrous hyperplasia, mucoid arterial intimal fibrosis, multifocal thickening/splitting of peritubular capillary basement membranes - Sparse chronic inflammatory infiltrate, <1/3 of cases - End-stage: symmetric contracted kidneys, 20–30 g each, smooth outlines - Urothelial tumors: typically high-grade transitional cell carcinoma

10.6 Genetic testing

Germline genetic testing has no diagnostic role in BEN. There is no gene panel, no WES/WGS indication, no CMA, no karyotype, no FISH, no mtDNA test, no repeat-expansion test. The only sequencing that matters is somatic tumor sequencing for the AA signature. Say this explicitly in the entry — the OMIM framing invites the opposite assumption.

10.7 Diagnostic and classification criteria — the 2013/2014 consensus

Jelaković et al., Nephrol Dial Transplant 2014;29(11):2020–7 (PMID:24166461), from the 2008 Brač workshop. Table 2 as reproduced in PMID:31054628:

I. Diseased/affected BEN cases — any one of: 1. Biopsy proven / indicative of BEN, or 2. Residency in a BEN household >20 years + tubular proteinuria + decreased eGFR + anemia, or 3. Residency in a BEN village >20 years + UTUC + tubular proteinuria

II. Suspected BEN — any one of: 1. Residency in a BEN household >20 years + reduced eGFR + anemia, or 2. Residency in a BEN household >20 years + tubular proteinuria, or 3. Residency in a BEN village >20 years + UTUC

III. High-risk group — residency in a BEN household >20 years; or residency in a household with sporadic/suspected BEN cases >20 years

IV. Sporadic BEN — biopsy proven/indicative of BEN in a patient with UTUC outside the endemic region, or in a member of their household

Footnote definitions: tubular proteinuria = α1-microglobulin >31.5 mg/g and α1-microglobulin/urine albumin ratio ≥0.91. Anemia = Hb <120 g/L (men and women >50 y), <110 g/L (women ≥50 y).

10.8 The general AAN diagnostic criteria (Gökmen et al., PMID:23552405)

Diagnosis is certain with renal failure plus any two of three: 1. Renal histology showing interstitial fibrosis with a corticomedullary gradient 2. History of ingesting vegetal/herbal products whose phytochemical analysis demonstrated AA 3. Presence of aristolactam-DNA adducts (or the specific TP53 A:T→T:A mutation) in kidney tissue or a urothelial cancer

With one criterion, diagnosis is "highly probable." Either AA-in-plant or adducts-in-tissue is described as "central to a diagnosis that provides absolute certainty." (PMID:31054628)

10.9 Differential diagnosis

Everything that produces chronic tubulointerstitial fibrosis. From PMID:31054628, must exclude:

The combination of chronic tubulointerstitial nephropathy + UTUC is the pattern that should immediately raise AAN/BEN. Two individually rare things co-occurring is the whole epidemiological argument in miniature.

10.10 Screening

Per PMID:24166461 / PMID:31054628:

• Whole adult population of BEN villages: mass screening every 5 years. Panel = tubular proteinuria (α1-microglobulin) + eGFR (CKD-EPI) + RBC count + dipstick urinalysis + urine cytology.
• "Diseased" → refer to local nephrologist.
• "BEN suspected" and BEN-household members without tubular proteinuria or UTUC → yearly screening.
• ESRD of unknown origin from non-endemic villages, plus their household members → screen for sporadic BEN/UTUC.
• High UTUC risk (biopsy indicative of BEN; BEN with CKD ≥3A; BEN transplanted or on dialysis) → every 6 months with urine cytology, ultrasound, other imaging as needed; their household members yearly.
• Previous UTUC, bladder cancer, or hematuria → every 3 months; hematuria → cystoscopy; high UTUC suspicion → ureteropyeloscopy + CT.

No newborn screening, no carrier screening, no cascade genetic screening. NCIT:C48261 Screening; NCIT:C15406 Cancer Screening.

11. Outcome / Prognosis

11.1 Survival and mortality

• Untreated: invariable progression to ESRD and death.
• With renal replacement: survival is that of the ESRD population, modified upward by BEN's unusual cardiovascular profile — "lower arterial stiffness and slower vascular aging ... compared to other ESRD patients" (PMID:31054628), attributable to later-onset, milder hypertension.
• Modified downward by cancer: UTUC mortality in the Croatian endemic county was 55× higher than the rest of Croatia (PMID:31054628). UTUC is the disease's leading cause of excess death.
• I did not locate BEN-specific 5-/10-year survival figures. Report this as a gap rather than substituting general ESRD statistics.

11.2 Morbidity

• ESRD with lifelong dialysis dependence or transplantation
• Anemia disproportionate to CKD stage → fatigue, reduced exercise capacity
• Bilateral nephroureterectomy in transplant candidates — a large, permanent, iatrogenic morbidity imposed by the cancer risk
• Recurrent urothelial tumors, including bladder cancer years after native nephroureterectomy (PMID:31054628)
• No GBD-specific BEN disability estimates located

11.3 Complications

Renal: ESRD, renal anemia, late hypertension, salt wasting, CKD-MBD (by extension, not BEN-specific). Oncologic: UTUC (30–50%, often bilateral), bladder carcinoma (particularly post-transplant Belgian cohort), possibly RCC (§4.4). Transplant-specific: de-novo urothelial malignancy under immunosuppression — the reason mTOR inhibitors are preferred.

11.4 Recovery potential

None. Renal injury is irreversible; exposure cessation halts accrual but does not reverse fibrosis. Adducts persist for decades, so cancer risk does not fall when exposure stops — arguably the most clinically important prognostic fact in the whole disease.

11.5 Prognostic factors

12. Treatment

Bottom line: there is no disease-modifying therapy. The intervention set is exposure elimination, generic CKD/ESRD care, and aggressive cancer surveillance and surgery.

"there is no effective treatment for delaying or reversing the renal deterioration caused by AAN." — PMID:37448287

12.1 Exposure elimination

The only genuinely causal intervention. Not pharmacological — agricultural and dietary.

12.2 Renal replacement therapy

"Patients with established BEN should be treated like other CKD patients, with peritoneal dialysis, hemodialysis or renal transplantation in ESRD stage." (PMID:24166461, via PMID:31054628)

12.3 Transplant-specific protocol — this is where BEN diverges from ordinary CKD

All from PMID:31054628 / PMID:24166461:

• BEN patients must be screened to exclude urothelial cancer before waitlisting.
• Bilateral nephroureterectomy should be performed prior to transplantation — in all recipients <65 years, and in those >65 if UTUC or bladder cancer is already diagnosed or there is a family history of UTUC. NCIT:C51646 Nephroureterectomy; NCIT:C159437 Nephroureterectomy with Cuff of Bladder.
• Living donors who lived in a BEN region >15–20 years should have a donor kidney biopsy to exclude BEN and/or AA-DNA adducts. (An unusual and rather striking recommendation — the donor may be silently affected.)
• Patients who refuse bilateral nephroureterectomy require close post-transplant urothelial monitoring.
• mTOR inhibitors should be considered for immunosuppression in BEN transplant recipients (antineoplastic properties). therapeutic_modality: SMALL_MOLECULE.

12.4 UTUC treatment

• Standard: total nephroureterectomy with excision of a bladder cuff around the ureteral ostium plus regional lymphadenectomy. NCIT:C159437; NCIT:C15329 Surgical Procedure.
• Conservative/kidney-sparing surgery: reserved for highly selected patients with bilateral tumors; higher local recurrence, requires close monitoring.
• Systemic chemotherapy: for unresectable/metastatic disease. NCIT:C15632 Chemotherapy.
• Non-invasive bladder cancer (Belgian AAN cohort experience): endoscopic resection + endovesical mitomycin C instillation; BCG (NCIT:C298 BCG Vaccine) also used successfully, including in renal-graft recipients when combined with modulation of immunosuppression and prophylactic anti-tuberculosis chemotherapy.
• Radical cystectomy with pyelostomy of the graft — the ultimate measure for invasive bladder cancer in transplant recipients.

12.5 Immunotherapy — a live, biologically motivated hypothesis

AA-UTUC carries an extreme mutation burden with 68–76% of AA-specific deleterious mutations propagating to the transcript level — "a possible basis for neoantigen formation and immunotherapy targeting" (PMID:34569060). Curate as an emerging hypothesis with status: EMERGING, not as established practice. I found no completed BEN-specific checkpoint-inhibitor trial.

12.6 Experimental / preclinical (nephroprotection)

None of these has clinical evidence in BEN. All are rodent or cell-model results — curate with evidence_source: MODEL_ORGANISM or IN_VITRO, never as treatment recommendations.

Dicoumarol and probenecid are the two mechanistically pointed ones — they attack the exact bioactivation and uptake steps identified in §6.1 steps 3 and 5. That coherence is itself a form of mechanistic validation, even though neither is a clinical option.

12.7 Pharmacogenomics

No CPIC guideline, no FDA PGx biomarker, no PharmGKB entry for BEN. The GPX3/MDR1/NQO1/CYP1A polymorphism story is risk-stratification, not drug dosing. Do not present it as pharmacogenomics.

12.8 Clinical trials

I found no BEN-specific interventional trial registered on ClinicalTrials.gov in this session. If curating clinical_trials:, leave the section empty rather than importing generic CKD or UTUC trials — an honest empty section beats a padded one.

13. Prevention

13.1 Primary prevention — the one that actually worked

Eliminating AA from the food chain, achieved (accidentally) through agricultural modernization:

"important improvements occurred in the 1970s: 1) large common mills were built and used instead of small village mills; 2) combines became popular with much smaller holes in sieving machines enabling better separation of much bigger Aristolochia from the wheat seeds" (PMID:31054628)

And the crucial nuance, which is a genuinely good insight for public health: the plant is still there.

"the presence of Aristolochia in farming fields is a risk factor but only if associated with particular agricultural practices and life style." (PMID:31054628)

You do not need to eradicate the weed. You need to sieve properly. That is a far cheaper and more tractable intervention, and it is why the disease is disappearing without anyone having deliberately set out to make it disappear.

Other primary measures: - Regulatory bans on AA-containing herbal products (FDA 2001 and international equivalents) - Public health education in endemic regions — NCIT:C16664 Health Education; NCIT:C18975 Public Health Education - Soil/crop monitoring where AA uptake into edible crops is documented (PMID:27362729) - Weed management in wheat fields

13.2 Secondary prevention

The 5-yearly mass screening program (§10.10). This is the textbook case for population screening: a long asymptomatic phase, a cheap urine-based marker, a defined at-risk population, and a severe outcome.

13.3 Tertiary prevention

• Intensive UTUC surveillance schedules stratified by risk (6-monthly / 3-monthly)
• Prophylactic bilateral nephroureterectomy in transplant candidates
• mTOR-inhibitor-based immunosuppression post-transplant
• Standard CKD progression management (BP control, RAAS blockade, anemia management) — extrapolated from general CKD care, not BEN-specific evidence

13.4 Not applicable

Immunization — no infectious etiology, no vaccine. (BCG here is intravesical immunotherapy for bladder cancer, not immunization — don't let the shared name confuse the curation.) Genetic counseling / prenatal / PGD / carrier screening — no germline causal gene. NCIT:C15240 Genetic Counseling should not be curated as a treatment or prevention for BEN. Household screening is environmental cascade screening, not genetic.

13.5 Prophylaxis

No chemoprophylaxis exists. Dicoumarol and probenecid are preclinical only (§12.6).

14. Other Species / Natural Disease

This is a small but genuinely interesting section — the veterinary observation preceded the human hypothesis by a decade.

14.1 Horses — the historical first observation

"Already ten years before, Martinčić and Dumić had reported horse poisoning with Aristolochia clematitis and found strict similarities in epidemiology, clinic, laboratory data and renal pathology between horses and BEN." (PMID:31054628)

Species: Equus caballus. NCBI Taxonomy ID not verified this session — look up before binding. Naturally occurring, environmental, in the same Balkan region, from the same plant. This is a strong animal_models: candidate with relationship: RECAPITULATES and high face validity — same species-of-plant, same route, same organ, same pathology — though as a mid-20th-century veterinary report the evidence grade is limited.

14.2 Goats

Combined toxicity of Aristolochia bracteata and Calaba rotundifolia in goats, Sudan (El Dirdiri et al., Vet Hum Toxicol 1987, cited in PMID:31054628). A different Aristolochia species, a different continent, the same genus and toxin class. Species: Capra hircus.

14.3 Comparative biology

• The AA activation pathway (nitroreduction by NQO1/POR/CYP) is conserved across rodents, rabbits, and humans — which is why the rodent models are as faithful as they are.
• A caveat worth curating as a limitation: in rodents, the characteristic A:T→T:A transversion lands in codon 61 of H-ras; in humans it lands in TP53. Same mutational mechanism, different target gene, because different genes drive tumorigenesis in each species (PMID:31054628). A model that reproduces the signature is not automatically reproducing the driver.
• Nitroreduction is described as essential for rapid AAI clearance "in different species including humans" — the same reaction is both the clearance route and the poisoning route, which is an unusually elegant piece of toxicological irony.

14.4 Zoonotic potential

None. BEN is a toxic exposure, not transmissible. Cross-species susceptibility exists only in the sense that any mammal eating Aristolochia is at risk.

14.5 OMIA

I did not locate an OMIA entry for aristolochic acid nephropathy in the horse. Report as not found rather than absent.

15. Model Organisms

15.1 The flagship experimental model — rodent AAN

Model type: mammalian, in vivo, chemically induced (not genetic).

Species: male Wistar rat, and mouse (various strains); rabbit also used. "Human AAN has been reproduced in several animal models including rabbits, mice and rats."

Biphasic course — this is what makes it valuable:

"an early phase of acute tubular necrosis was rapidly followed by a massive interstitial recruitment of activated monocytes/macrophages followed by cytotoxic T lymphocytes, resulting in a transient AKI episode. A later chronic phase was then observed with progressive tubular atrophy related to dedifferentiation and necrosis of tubular epithelial cells." — PMID:35602498

Phenotype recapitulation:

Limitations to record explicitly: the rodent models reproduce iatrogenic AAN's dose regimen, not BEN's. They are excellent models of AA nephrotoxicity and of AKI-to-CKD transition; they are poor models of chronic low-dose environmental exposure. This is exactly the situation dismech's HUMAN_MODEL_MISMATCH discussion kind exists for — evidence exists in the model, but translational validity to the specific human disease (the slow, low-dose form) is the open question.

Primary applications: AKI-to-CKD transition mechanisms; nephroprotective drug screening; immune-infiltrate characterization; metabolomic biomarker discovery.

15.2 The Hupki (human TP53 knock-in) mouse embryo fibroblast system

The most elegant model for the carcinogenic branch, because it solves the species-driver-gene mismatch by putting the human gene in:

"studying AA-induced TP53 mutagenesis using human TP53 knock-in (Hupki) mouse embryo fibroblasts (HUFs) not only confirmed the TP53 mutation signature of AA in HUFs immortalized after AAI exposure in vitro but also that AAI-treated HUFs share so-called hotspot TP53 mutations observed in UTUC from BEN patients. These findings explain the molecular mechanism whereby AA causes urothelial cancer." (PMID:31054628)

Model type: genetic (knock-in) × in vitro. Fidelity for the mutational-signature node: HIGH. Fidelity for tissue-level urothelial carcinogenesis: LOW (fibroblasts, not urothelium).

15.3 In vitro / cellular systems

For dismech, the HEK293-hOAT system is worth a dedicated experimental_models: entry with modeled_mechanisms → the OAT-uptake pathophysiology node, relationship: PERTURBS, fidelity: HIGH, and a probenecid RESCUES readout.

15.4 Genetic models

• Hupki TP53 knock-in mice (above)
• Glycine N-methyltransferase (GNMT) models — GNMT inhibits AAN by increasing CYP3A44 and decreasing NQO1 expression in female mouse hepatocytes (PMC5934382) — a nice in vivo confirmation of the activation/detoxification balance hypothesis
• NQO1 knockout — not verified this session; would be the obvious experiment
• No BEN-specific zebrafish, Drosophila, C. elegans, or yeast model located
• No BEN-specific iPSC, organoid, or kidney-on-chip model located — a real and rather glaring gap given how well the disease's proximal-tubule selectivity would suit a proximal-tubule-on-chip with OAT expression

15.5 Model databases

MGI, RGD (for chemically induced AAN protocols), Cellosaurus (HK-2), IMPC/KOMP (for Nqo1, Slc22a6, Slc22a8 alleles). No BEN-specific model repository exists.

Appendix A — Curation notes and honest caveats

Things a downstream curator should know before writing YAML:

1. The BEN / AAN lumping question is unresolved and consequential (§1.3–1.4). MONDO treats them as synonyms; the clinical literature treats them as dose-differentiated forms of one etiologic entity. Consider has_subtypes or a Grouping.
2. OMIM 124100 is actively misleading on mechanism (§1.2). Cite it for identity only.
3. CHEBI:2825's canonical label is "aristolochic acid A", not "aristolochic acid I." dismech's exact-label rule bites here.
4. Verified vs unverified ontology IDs. Every HP, CL, UBERON, ECTO, and NCIT ID given above was resolved against OLS4 in this session except where explicitly marked (not verified) — notably GO:0006915, GO cellular-component terms, macrophage/T-cell CL terms, NCBI Taxonomy IDs, and the NCIT hemodialysis term. Run just validate-terms regardless.
5. The rodent models are models of iatrogenic AAN, not of BEN (§15.1). Any animal_models entry should carry that limitation explicitly, and probably a HUMAN_MODEL_MISMATCH discussion.
6. Negative results worth curating as REFUTE: ochratoxin A as primary cause; herbal-tea use as a BEN risk factor in the Balkans; heavy metals; infectious agents.
7. The dissent on Pliocene lignite is live, not dead. Present the consensus rejection, but don't erase the geochemistry literature.
8. Genuine literature gaps — say so rather than inventing: BEN-specific QoL instruments; BEN-specific 5-/10-year survival; GBD disability estimates; modern GWAS; single-cell/spatial transcriptomics; organoid or organ-chip models; BEN-specific clinical trials; Orphanet listing.
9. The SBS22-as-low-risk-subtype finding (PMID:32292497) runs against intuition and against the general "more mutations = worse" prior. Curate it, but note the tension rather than smoothing it over.

Appendix B — Reference list (PMID-verified)

All titles, years, and journals below were verified against NCBI eSummary/eFetch in this session.

Already in your local cache: references_cache/PMID_17620607.md (abstract) and references_cache/PMID_31054628.md (full text, 71 KB — this one is the workhorse; most of the §3–§13 quotes come straight out of it).

Sources (web):

• Aristolochic acid and the etiology of endemic (Balkan) nephropathy — PNAS
• Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid — ScienceDirect
• Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy — NDT
• Geographic variation of mutagenic exposures in kidney cancer genomes — Nature · PMC
• Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid — Kidney International
• Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) — NEJM
• GPX3 rs8177412 polymorphism modifies risk of upper urothelial tumors in patients with BEN — Medicina/PMC
• Overview of aristolochic acid nephropathy: an update — Kidney Res Clin Pract
• Experimental aristolochic acid nephropathy: a relevant model to study AKI-to-CKD transition — PMC
• Molecular evidence for an involvement of organic anion transporters (OATs) in AAN — PubMed
• Physiological and molecular characterization of aristolochic acid transport by the kidney — PMC
• Inhibition of renal NQO1 activity by dicoumarol — Toxicological Sciences
• NGS nominated CELA1, HSPG2, and KCNK5 as candidate genes for predisposition to BEN — PMC
• Whole genome methylation array analysis reveals new aspects in BEN etiology — BMC Nephrology
• Aristolochic acid exposure in Romania and implications for renal cell carcinoma — Br J Cancer
• Aristolochic acid mutational signature defines the low-risk subtype in UTUC — Theranostics
• The etiology of Balkan endemic nephropathy: still more questions than answers — EHP/PMC
• A possible link between BEN and leaching of toxic organic compounds from Pliocene lignite — USGS
• Balkan endemic nephropathy: an update on its aetiology — PMC
• Aristolochic acid–associated cancers: a public health risk in need of global action — IARC
• Plants containing aristolochic acid — IARC Monographs / NCBI Bookshelf
• OMIM Entry 124100 — Danubian endemic familial nephropathy
• AAI induces proximal tubule injury through ROS/HMGB1/mtDNA mediated activation of TLRs — PMC

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

1 of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:31054628: "In 1969, Ivic had suggested that the latter, occurring in certain villages throughout the Danube Valley, might be caused by the chronic ingestion of the seeds of the Aristolochia clematitis, a common plant growing in the wheat fields of these endemic regions."
• closest text in source: "1,4 In 1969, Ivic had suggested that the latter, occurring in certain villages throughout the Danube V alley, might be caused by the chronic ingestion of the seeds of the Aristolochia clematitis, a common plant growing in the wheat fields of these endemic regions"
• PMID:24166461 (abstract only): "Patients with established BEN should be treated like other CKD patients, with peritoneal dialysis, hemodialysis or renal transplantation in ESRD stage."
• closest text in source: "National medical providers should cover costs of screening and diagnostic procedures and treatment of EN patients with or without upper urothelial cancers."
• PMID:31054628: "Already ten years before, Martinčić and Dumić had reported horse poisoning with Aristolochia clematitis and found strict similarities in epidemiology, clinic, laboratory data and renal pathology between horses and BEN."
• closest text in source: "Already ten years before, Martin čić and Dumi ć had reported horse poisoning with Aristolochia clematitis and found strict 10 similarities in epidemiology, clinic, laboratory data and renal pathology between horses and BEN"
• PMID:31054628: "studying AA-induced TP53 mutagenesis using human TP53 knock-in (Hupki) mouse embryo fibroblasts (HUFs) not only confirmed the TP53 mutation signature of AA in HUFs immortalized after AAI exposure in vitro but also that AAI-treated HUFs share so-called hotspot TP53 mutations observed in UTUC from BEN patients. These findings explain the molecular mechanism whereby AA causes urothelial cancer."
• closest text in source: "56 Further, studying AA-induced TP53 mutagenesis using human TP53 knock-in (Hupki) mouse embryo fibroblasts (HUFs) not only confirmed the TP53 mutation signature of AA in HUFs immortalized after AAI exposure in vitro 58 but also that AAI-treated HUFs share so-called hotspot TP53 mutations observed in UTUC from BEN patients.59 These findings explain the molecular mechanism whereby AA causes urothelial cancer.49 (Figure 2)"